Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

Could the Silver Price Really Hit US$100 per Ounce? (Updated 2024)

Top 10 Copper-producing Companies (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Top 10 Countries for Natural Gas Production (Updated 2024)

Where Does Tesla Get its Lithium? (Updated 2024)

7 Biggest Lithium-mining Companies

Top 5 Canadian Uranium Stocks of 2024

11 Canadian Cryptocurrency ETFs (Updated 2024)

Hydrogen Stocks: 9 Biggest Companies

Trending Press Releases

Galan Increases Total Mineral Resource by 18% to 8.6Mt LCE @ 859mg/L Lithium

Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Edison Lithium Expands Portfolio with Acquisition of Additional Sodium Brine Claim in Saskatchewan

Health House Australia and Corporate Update

Significant Mineral Resource Upgrade for Project Iron Bear

Bitcoin Well Launches Cash Vouchers For Canadian Customers

More Press Releases
Trending Companies

Cyclone Metals

CLE:AU

Lancaster Resources

LCR:CC

Purpose Bitcoin ETF

BTCC:CA

Element79 Gold Corp.

ELEM:CC
More Companies
Trending Reports

2024 EV Market Outlook Report

2024 Rare Earths Outlook: Australia Edition

2024 Gold Outlook: Australia Edition

2024 Lithium Market Outlook

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold
Copper
Uranium
Oil and Gas
Artificial Intelligence
Biotech
loader

mrk

LATEST ARTICLES
Pharmaceutical Investing

Merck's KEYTRUDA® Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer

Pharmaceutical Investing

Moderna and Merck Announce mRNA-4157 , an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA , Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA

Pharmaceutical Investing

FDA Accepts Application for Merck's KEYTRUDA® Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Pharmaceutical Investing

EMD Electronics Expands Semiconductor Manufacturing Capacities for the World's Largest Integrated Specialty Gases Facility in Hometown, Pennsylvania

Pharmaceutical Investing

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® Plus LENVIMA® In Certain Patients With Advanced Melanoma and Metastatic Colorectal Cancer

Pharmaceutical Investing

MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda , Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

Pharmaceutical Investing

Merck: Aiming for Health Equity and Business Success

Pharmaceutical Investing

FDA Approves Merck's KEYTRUDA® in Combination With Padcev® for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science

MARKETS

Markets
TSX21740.20-159.79
TSXV576.67-11.04
DOW37735.11-248.13
S&P 5005061.82-61.59
NASD15885.02-290.08
ASX7788.10-25.50

COMMODITIES

Commodities
Gold2381.47-0.34
Silver28.74-0.15
Copper4.36-0.02
Oil86.06+0.65
Heating Oil2.67+0.02
Natural Gas1.690.00